The figure of 1,000 donors appeared on a product label for Kryobulin Red (made with European plasma). Read more about The figure of 1,000 donors appeared on a product label for Kryobulin Red (made with European plasma).
Dr Kingdon occupied various positions in Hyland Therapeutics. Read more about Dr Kingdon occupied various positions in Hyland Therapeutics.
When AIDS cases first came to public attention in 1981 immigrants from Haiti were found to be at high risk of infection and hence unsuitable as donors. Read more about When AIDS cases first came to public attention in 1981 immigrants from Haiti were found to be at high risk of infection and hence unsuitable as donors.
Hyland Therapeutics closed that their sole plant in Lesotho. Read more about Hyland Therapeutics closed that their sole plant in Lesotho.
Hyland Therapeutics closed the Mexico City plant (which used Mexican sourced plasma). Read more about Hyland Therapeutics closed the Mexico City plant (which used Mexican sourced plasma).
Hyland Therapeutics closed a plasma centre in Puerto Rico. Read more about Hyland Therapeutics closed a plasma centre in Puerto Rico.
Professor Bloom stated that Profilate HT had the largest share of the commercial market. Read more about Professor Bloom stated that Profilate HT had the largest share of the commercial market.
Armour,/Alpha, Travenol/Hyland, Miles/Cutter and Immuno all confirmed that their plasma came from plants that were licensed by the FDA and that the origins of their plasma were identifiable Read more about Armour,/Alpha, Travenol/Hyland, Miles/Cutter and Immuno all confirmed that their plasma came from plants that were licensed by the FDA and that the origins of their plasma were identifiable
In terms of the distribution of market share for commercial Factor 8 products, Factorate accounted for 42%, Koate for 18% and Profilate and Kryobulin both accounted for around 11% of total usage. Read more about In terms of the distribution of market share for commercial Factor 8 products, Factorate accounted for 42%, Koate for 18% and Profilate and Kryobulin both accounted for around 11% of total usage.
The licensing authority required references to heat treatment to be that it was intended to "reduce the risk of transmission of infectious agents" rather than making claims about it reducing the risks of HIV or non-A non-B Hepatitis by name. Read more about The licensing authority required references to heat treatment to be that it was intended to "reduce the risk of transmission of infectious agents" rather than making claims about it reducing the risks of HIV or non-A non-B Hepatitis by name.